Clinical trials: Post Hematopoietic Stem Cell Transplant
Graft Versus Host Disease, Nonneoplastic Condition
T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant
RATIONALE: An infusion of cytomegalovirus-specific T lymphocytes may prevent or reduce cytomegalovirus infection during the first year after a donor stem cell transplant.
- Trial name
- NCT00986557
- Testing
- adoptive immunotherapy, alemtuzumab, in vitro-treated peripheral blood lymphocyte therapy
- Where
- United Kingdom
- Volunteers
- 78 people
- Sponsor
- University Hospital Birmingham
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation
FMT In High-Risk Acute GVHD After ALLO HCT
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD). This research study involves an experimental intervention called FMT.
- Conditions
- Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
- Trial name
- NCT04139577
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma and Plasma Cell Neoplasm
High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
RATIONALE: Giving chemotherapy and bortezomib before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them.
- Trial name
- NCT00747877
- Testing
- cyclophosphamide, melphalan, autologous hematopoietic stem cell transplantation
- Where
- 53 sites in United Kingdom
- Volunteers
- 460 people
- Sponsor
- Leeds Cancer Centre at St. James's University Hospital
Breast Cancer
Chemotherapy Followed by Peripheral Stem Cell Transplantation Plus Biological Therapy in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation plus biological therapy may allow the doctor…
- Trial name
- NCT00020722
- Testing
- therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Thrombocytopenia, Stem Cell Transplant Complications
Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy
Isolated prolonged thrombocytopenia (PT) is a common complication after allogeneic stem cell transplantation with significant poor prognosis. No standard treatment is available.
- Trial name
- NCT03391856
- Testing
- N-acetyl-L-cysteine (NAC), supportive therapy
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Peking University People's Hospital
Primary Myelofibrosis, Secondary Myelofibrosis
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
This early phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with primary or secondary myelofibrosis.
- Trial name
- NCT03426969
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Newly Diagnosed
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT.
- Trial name
- ElLen (NCT06918002)
- Testing
- Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex)
- Where
- 69 sites in Belgium, France
- Volunteers
- 824 people
- Sponsor
- Intergroupe Francophone du Myelome
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Cytomegalovirus Infections
Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
The purpose of this trial is to determine if preemptive therapy with oral valganciclovir is as effective as intravenous ganciclovir in clearing cytomegalovirus (CMV) viremia as determined by quantitative CMV polymerase chain…
- Trial name
- NCT00241345
- Testing
- Valganciclovir, Ganciclovir
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed…
- Trial name
- NCT06483100
- Testing
- Elrantamab, clonoSEQ
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Washington University School of Medicine
Hematologic Malignancy, Stem Cell Transplant Complications
Azacitidine in Combination With Venetoclax Treatment for MRD Positive Post Allo-HSCT AML/MDS Patients
In patients with MRD-positive patients after AML/MDS allogeneic hematopoietic stem cell transplantation, azacytidine combined with venetoclax may be effective in eliminating micro residual diseases, reducing the risk of relapse…
- Trial name
- NCT04809181
- Testing
- Azacitidine in Combination With Venetoclax
- Where
- China
- Volunteers
- 95 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Hematologic Neoplasms
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD).
- Trial name
- NCT04959175
- Testing
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
This phase Ib trial tests the safety, side effects, best dose and effectiveness of tagraxofusp in combination with azacitidine as maintenance therapy in treating patients with CD123 positive acute myeloid leukemia (AML) and…
- Trial name
- NCT06498973
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- City of Hope Medical Center
Leukemia
Efficacy and Safety Evaluation of IM19 CAR-T Cell Therapy for MRD+ After Transplantation
Efficacy study about donor derived CD19-target T cell to treat B-ALL post hematopoietic stem cell transplantation
- Trial name
- NCT04336501
- Testing
- IM19 CAR-T
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Graft Vs Host Disease
Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT
This research project delves into the critical role of gut immunity in the occurrence and progression of acute graft-versus-host disease (aGVHD) post allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- NCT06143501
- Testing
- Blood Sample, Stool Sample, Urine Sample
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Methods of T Cell Depletion Trial (MoTD)
A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- MoTD (NCT04888741)
- Testing
- Thymoglobulin, Cyclophosphamide, Cyclosporine
- Where
- 17 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- University of Birmingham
The Incidence of Peripheral Blood CMV Activation and Confirmed Clinically Significant CMV Infection Within 24 Weeks After Transplantation
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
To evaluate the efficacy and safety of primary prophylaxis of CMV reactivation, clinically significant CMV infection with oral letermovir in Chinese R+ haplo-HSCT patients, as well as treatment-related mortality and all-cause…
- Trial name
- NCT05914675
- Testing
- Letermovir
- Volunteers
- 21 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematological Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
This investigator-initiated, prospective, multicenter, open-label, randomized, controlled clinical study is designed to evaluate the clinical efficacy and safety of hetrombopag for promoting platelet engraftment after allo-HSCT…
- Trial name
- NCT05727917
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Aplastic Anemia
Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years
Outcomes for adult patients with Severe Aplastic Anemia (SAA) aged more than 40 years who are refractory or in relapse after first-line IST remain poor.
- Trial name
- APARR (NCT06646497)
- Testing
- Allogeneic hematopoietic stem cell transplantation Stem cell source only Bone Marrow
- Where
- 26 sites in France
- Volunteers
- 52 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma
PTK/ZK as Post Transplant Maintenance Therapy in Patients With Multiple Myeloma
The purpose of this study it to evaluate the efficacy of PTK787/ZK 222584, in inducing at least a 50% reduction in paraprotein in patients with multiple myeloma whose paraprotein levels are < 5 g/dL following high dose…
- Trial name
- NCT00240162
- Testing
- PTK787/ZK 222584
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Washington University School of Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.